Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 9, 2010, Pages 997-1008

  John, Chandy C ^a   Kutamba, Elizabeth ^b   Mugarura, Keith ^b   Opoka, Robert O ^b  

^a Center for Global Pediatrics   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

Author keywords

adjunctive; cerebral; human; malaria; Plasmodium falciparum; severe; treatment

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALBUMIN; ARGININE; ARTESUNATE; CURDLAN; DEFERIPRONE; DEFEROXAMINE; DEXAMETHASONE; DICHLOROACETIC ACID; ERYTHROCYTE MEMBRANE PROTEIN 1 INHIBITOR; GELATIN SUCCINATE; GLYCOSAMINOGLYCAN; HEPARIN; IMMUNOGLOBULIN; INSECTICIDE; LACTIC ACID; LEVAMISOLE; MANNITOL; NITRIC OXIDE; PANTETHINE; PENTOXIFYLLINE; PHENOBARBITAL; PLACEBO; PROTEIN INHIBITOR; QUININE; RECOMBINANT ERYTHROPOIETIN; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACIDOSIS; ADJUVANT THERAPY; BED NET; BRAIN EDEMA; BRAIN MALARIA; CELL ADHESION; CLINICAL TRIAL; COGNITIVE DEFECT; CONVALESCENCE; DISEASE SEVERITY; EXCHANGE BLOOD TRANSFUSION; HUMAN; IMMUNOMODULATION; INHIBITION KINETICS; INTRACRANIAL PRESSURE; IRON CHELATION; IRON OVERLOAD; LACTIC ACIDOSIS; MALARIA FALCIPARUM; MORTALITY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PLASMODIUM FALCIPARUM; REVIEW; SEIZURE; THROMBOSIS; TREATMENT OUTCOME;

EID: 77956484683     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.90     Document Type: Review

References (85)

1. WHO. World malaria report 2008. WHO, Geneva, Switzerland (2008).
2. Snow RW, Marsh K. The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv. Parasitol. 52, 235-264 (2002).
3. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434(7030), 214-217 (2005).
4. Idro R, Aloyo J, Mayende L, Bitarakwate E, John CC, Kivumbi GW. Severe malaria in children in areas with low, moderate and high transmission intensity in Uganda. Trop. Med. Int. Health 11(1), 115-124 (2006).
5. Murphy SC, Breman JG. Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and complications of pregnancy. Am. J. Trop. Med. Hyg. 64(1-2 Suppl.), 57-67 (2001).
6. Reyburn H, Mbatia R, Drakeley C et al. Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. JAMA 293(12), 1461-1470 (2005).
7. Oduro AR, Koram KA, Rogers W et al. Severe falciparum malaria in young children of the Kassena-Nankana district of northern Ghana. Malar. J. 6, 96 (2007).
8. Kahigwa E, Schellenberg D, Sanz S et al. Risk factors for presentation to hospital with severe anaemia in Tanzanian children: a case-control study. Trop. Med. Int. Health 7(10), 823-830 (2002).
9. John CC, Bangirana P, Byarugaba J et al. Cerebral malaria in children is associated with long-term cognitive impairment. Pediatrics 122(1), e92-e99 (2008).
10. Imbert P, Sartelet I, Rogier C, Ka S, Baujat G, Candito D. Severe malaria among children in a low seasonal transmission area, Dakar, Senegal: infuence of age on clinical presentation. Trans. R. Soc. Trop. Med. Hyg. 91(1), 22-24 (1997).
11. Boivin MJ, Bangirana P, Byarugaba J et al. Cognitive impairment after cerebral malaria in children: a prospective study. Pediatrics 119(2), e360-e366 (2007).
12. Boivin MJ. Effects of early cerebral malaria on cognitive ability in Senegalese children. J. Dev. Behav. Pediatr. 23(5), 353-364 (2002).
13. Van Hensbroek MB, Palmer A, Jaffar S, Schneider G, Kwiatkowski D. Residual neurologic sequelae after childhood cerebral malaria. J. Pediatr. 131(1 Pt 1), 125-129 (1997). (Pubitemid 27498320)
14. Roze E, Thiebaut MM, Mazevet D et al. Neurologic sequelae after severe falciparum malaria in adult travelers. Eur. Neurol. 46(4), 192-197 (2001).
15. Taylor TE, Fu WJ, Carr RA et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat. Med. 10(2), 143-145 (2004).
16. Grau GE, Taylor TE, Molyneux ME et al. Tumor necrosis factor and disease severity in children with falciparum malaria. N. Engl. J. Med. 320(24), 1586-1591 (1989).
17. Clark IA, Alleva LM. Is human malarial coma caused, or merely deepened, by sequestration? Trends Parasitol. 25(7), 314-318 (2009).
18. Clark IA, Budd AC, Alleva LM. Sickness behaviour pushed too far-the basis of the syndrome seen in severe protozoal, bacterial and viral diseases and post-trauma. Malar. J. 7, 208 (2008).
19. John CC, Opika-Opoka R, Byarugaba J, Idro R, Boivin MJ. Low levels of RANTES are associated with mortality in children with cerebral malaria. J. Infect. Dis. 194(6), 837-845 (2006).
20. John CC, Park GS, Sam-Agudu N, Opoka RO, Boivin MJ. Elevated serum levels of IL-1ra in children with Plasmodium falciparum malaria are associated with increased severity of disease. Cytokine 41(3), 204-208 (2008).
21. Jain V, Armah HB, Tongren JE et al. Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India. Malar. J. 7, 83 (2008).
22. Anstey NM, Weinberg JB, Hassanali MY et al. Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J. Exp. Med. 184(2), 557-567 (1996).
23. Medana IM, Hunt NH, Chan-Ling T Early activation of microglia in the pathogenesis of fatal murine cerebral malaria. Glia 19(2), 91-103 (1997).
24. Jennings VM, Lal AA, Hunter RL. Evidence for multiple pathologic and protective mechanisms of murine cerebral malaria. Infect. Immun. 66(12), 5972-5979 (1998).
25. Casals-Pascual C, Idro R, Gicheru N et al. High levels of erythropoietin are associated with protection against neurological sequelae in African children with cerebral malaria. Proc. Natl Acad. Sci. USA 105(7), 2634-2639 (2008).
26. John CC, Panoskaltsis-Mortari A, Opoka RO et al. Cerebrospinal fuid cytokine levels and cognitive impairment in cerebral malaria. Am. J. Trop. Med. Hyg 78(2), 198-205 (2008).
27. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366(9487), 717-725 (2005).
28. Praygod G, de Frey A, Eisenhut M. Artemisinin derivatives versus quinine in treating severe malaria in children: a systematic review. Malar. J. 7, 210 (2008).
29. White NJ, Turner GD, Medana IM, Dondorp AM, Day NP. The murine cerebral malaria phenomenon. Trends Parasitol. 26(1), 11-15 (2010).
30. Maitland K, Pamba A, English M et al. Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin beneft. Clin. Infect. Dis. 40(4), 538-545 (2005).
31. Warrell DA, Looareesuwan S, Warrell MJ et al. Dexamethasone proves deleterious in cerebral malaria. A double-blind trial in 100 comatose patients. N. Engl. J. Med. 306(6), 313-319 (1982).
32. Hoffman SL, Rustama D, Punjabi NH et al. High-dose dexamethasone in quinine-treated patients with cerebral malaria: a double-blind, placebo-controlled trial. J. Infect. Dis. 158(2), 325-331 (1988).
33. Taylor TE, Molyneux ME, Wirima JJ, Borgstein A, Goldring JD, Hommel M. Intravenous immunoglobulin in the treatment of paediatric cerebral malaria. Clin. Exp. Immunol. 90(3), 357-362 (1992).
34. Havlik I, Looareesuwan S, Vannaphan S et al. Curdlan sulphate in human severe/cerebral Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 99(5), 333-340 (2005).
35. Van Hensbroek MB, Palmer A, Onyiorah E et al. The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J. Infect. Dis. 174(5), 1091-1097 (1996).
36. Das BK, Mishra S, Padhi PK et al. Pentoxifylline adjunct improves prognosis of human cerebral malaria in adults. Trop. Med. Int. Health 8(8), 680-684 (2003).
37. Di Perri G, Di Perri IG, Monteiro GB et al. Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. J. Infect. Dis. 171(5), 1317-1322 (1995).
38. Hemmer CJ, Hort G, Chiwakata CB et al. Supportive pentoxifylline in falciparum malaria: no effect on tumor necrosis factor a levels or clinical outcome: a prospective, randomized, placebo-controlled study. Am. J. Trop. Med. Hyg. 56(4), 397-403 (1997).
39. Looareesuwan S, Wilairatana P, Vannaphan S et al. Pentoxifylline as an ancillary treatment for severe falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 58(3), 348-353 (1998). (Pubitemid 28160759)
40. Gordeuk VR, Loyevsky M. Antimalarial effect of iron chelators. Adv. Exp. Med. Biol. 509, 251-272 (2002).
41. Gordeuk V, Thuma P, Brittenham G et al. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N. Engl. J. Med. 327(21), 1473-1477 (1992).
42. Mohanty D, Ghosh K, Pathare AV, Karnad D. Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria. Indian J. Med. Res. 115, 17-21 (2002).
43. Thuma PE, Mabeza GF, Biemba G et al. Effect of iron chelation therapy on mortality in Zambian children with cerebral malaria. Trans. R. Soc. Trop. Med. Hyg. 92(2), 214-218 (1998).
44. Griffths MJ, Ndungu F, Baird KL, Muller DP, Marsh K, Newton CR. Oxidative stress and erythrocyte damage in Kenyan children with severe Plasmodium falciparum malaria. Br. J. Haematol. 113(2), 486-491 (2001).
45. Watt G, Jongsakul K, Ruangvirayuth R. A pilot study of N-acetylcysteine as adjunctive therapy for severe malaria. QJM 95(5), 285-290 (2002).
46. Charunwatthana P, Abul Faiz M, Ruangveerayut R et al. N-acetylcysteine as adjunctive treatment in severe malaria: a randomized, double-blinded placebo-controlled clinical trial. Crit. Care Med. 37(2), 516-522 (2009).
47. Combes V, Taylor TE, Juhan-Vague I et al. Circulating endothelial microparticles in malawian children with severe falciparum malaria complicated with coma. JAMA 291(21), 2542-2544 (2004).
48. Rogerson SJ, Reeder JC, al-Yaman F, Brown GV. Sulfated glycoconjugates as disrupters of Plasmodium falciparum erythrocyte rosettes. Am. J. Trop. Med. Hyg. 51(2), 198-203 (1994).
49. Hemmer CJ, Kern P, Holst FG, Nawroth PP, Dietrich M. Neither heparin nor acetylsalicylic acid infuence the clinical course in human Plasmodium falciparum malaria: a prospective randomized study. Am. J. Trop. Med. Hyg. 45(5), 608-612 (1991).
50. Riddle MS, Jackson JL, Sanders JW, Blazes DL. Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: a meta-analysis. Clin. Infect. Dis. 34(9), 1192-1198 (2002).
51. White NJ. The treatment of malaria. N. Engl. J. Med. 335, 800-806 (1996).
52. Maitland K, Nadel S, Pollard AJ, Williams TN, Newton CR, Levin M. Management of severe malaria in children: proposed guidelines for the United Kingdom. Br. Med. J. 331(7512), 337-343 (2005).
53. Akech S, Gwer S, Idro R et al. Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial. PLoS Clin. Trials 1(5), e21 (2006).
54. Woodrow CJ, Planche T. Phase III trial of albumin in malaria still lacks scientifc justifcation. PLoS Clin. Trials 2(2), e1 (2007).
55. Krishna S, Supanaranond W, Pukrittayakamee S, Kuile FT, Ruprah M, White NJ. The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. Br. J. Clin. Pharmacol. 41(1), 29-34 (1996).
56. Newton CR, Crawley J, Sowumni A et al. Intracranial hypertension in Africans with cerebral malaria. Arch. Dis. Child. 76(3), 219-226 (1997).
57. Namutangula B, Ndeezi G, Byarugaba JS, Tumwine JK. Mannitol as adjunct therapy for childhood cerebral malaria in Uganda: a randomized clinical trial. Malar. J. 6, 138 (2007).
58. Crawley J, Smith S, Kirkham F, Muthinji P, Waruiru C, Marsh K. Seizures and status epilepticus in childhood cerebral malaria. QJM 89(8), 591-597 (1996).
59. White NJ, Looareesuwan S, Phillips RE, Chanthavanich P, Warrell DA. Single dose phenobarbitone prevents convulsions in cerebral malaria. Lancet 2(8602), 64-66 (1988).
60. Crawley J, Waruiru C, Mithwani S et al. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet 355(9205), 701-706 (2000).
61. Idro R, Carter JA, Fegan G, Neville BG, Newton CR. Risk factors for persisting neurological and cognitive impairments following cerebral malaria. Arch. Dis. Child. 91(2), 142-148 (2006).
62. Chen Q, Pettersson F, Vogt AM et al. Immunization with PfEMP1-DBL1a generates antibodies that disrupt rosettes and protect against the sequestration of Plasmodium falciparum-infected erythrocytes. Vaccine 22(21-22), 2701-2712 (2004).
63. Barfod A, Persson T, Lindh J. In vitro selection of RNA aptamers against a conserved region of the Plasmodium falciparum erythrocyte membrane protein 1. Parasitol. Res. 105(6), 1557-1566 (2009).
64. Dondorp AM, Silamut K, Charunwatthana P et al. Levamisole inhibits sequestration of infected red blood cells in patients with falciparum malaria. J. Infect. Dis. 196(3), 460-466 (2007).
65. McCormick CJ, Newbold CI, Berendt AR. Sulfated glycoconjugates enhance CD36-dependent adhesion of Plasmodium falciparum-infected erythrocytes to human microvascular endothelial cells. Blood 96(1), 327-333 (2000).
66. Vogt AM, Barragan A, Chen Q, Kironde F, Spillmann D, Wahlgren M. Heparan sulfate on endothelial cells mediates the binding of Plasmodium falciparum-infected erythrocytes via the DBL1a domain of PfEMP1. Blood 101(6), 2405-2411 (2003).
67. Vogt AM, Pettersson F, Moll K et al. Release of sequestered malaria parasites upon injection of a glycosaminoglycan. PLoS Pathog. 2(9), e100 (2006).
68. Serghides L, Patel SN, Ayi K et al. Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria. J. Infect. Dis. 199(10), 1536-1545 (2009).
69. Boggild AK, Krudsood S, Patel SN et al. Use of peroxisome proliferator-activated receptor g agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 49(6), 841-849 (2009).
70. Marsh K, English M, Crawley J, Peshu N. The pathogenesis of severe malaria in African children. Ann. Trop. Med. Parasitol. 90(4), 395-402 (1996).
71. Penet MF, Abou-Hamdan M, Coltel N et al. Protection against cerebral malaria by the low-molecular-weight thiol pantethine. Proc. Natl Acad. Sci. USA 105(4), 1321-1326 (2008).
72. Vecsei L, Widerlov E. Preclinical and clinical studies with cysteamine and pantethine related to the central nervous system. Prog. Neuropsychopharmacol. Biol. Psychiatry 14(6), 835-862 (1990). (Pubitemid 20373157)
73. Weinberg JB, Lopansri BK, Mwaikambo E, Granger DL. Arginine, nitric oxide, carbon monoxide, and endothelial function in severe malaria. Curr. Opin Infect. Dis. 21(5), 468-475 (2008).
74. Yeo TW, Lampah DA, Gitawati R et al. Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. J. Infect. Dis. 198(4), 602-608 (2008).
75. Marks JD, Schreiber MD. Inhaled nitric oxide and neuroprotection in preterm infants. Clin. Perinatol. 35(4), 793-807, viii (2008).
76. Wiese L, Hempel C, Penkowa M, Kirkby N, Kurtzhals JAL. Recombinant human erythropoietin increases survival and reduces neuronal apoptosis in a murine model of cerebral malaria. Malar. J. 7, 3 (2008).
77. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299(8), 914-924 (2008).
78. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355(20), 2085-2098 (2006).
79. Ehrenreich H, Weissenborn K, Prange H et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40(12), e647-e656 (2009).
80. Picot S, Bienvenu AL, Konate S et al. Safety of epoietin b-quinine drug combination in children with cerebral malaria in Mali. Malar. J. 8, 169 (2009).
81. Casals-Pascual C, Idro R, Picot S, Roberts DJ, Newton CR. Can erythropoietin be used to prevent brain damage in cerebral malaria? Trends Parasitol. 25(1), 30-36 (2009).
82. Okiro EA, Alegana VA, Noor AM, Mutheu JJ, Juma E, Snow RW. Malaria paediatric hospitalization between 1999 and 2008 across Kenya. BMC Med. 7, 75 (2009).
83. O'Meara WP, Bejon P, Mwangi TW et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilif, Kenya. Lancet 372(9649), 1555-1562 (2008).
84. Ceesay SJ, Casals-Pascual C, Erskine J et al. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet 372(9649), 1545-1554 (2008).
85. Dondorp AM. Clinical signifcance of sequestration in adults with severe malaria. Transfus. Clin. Biol. 15(1-2), 56-57 (2008).